Authors: St Peter, JV Neafus, KL Khan, MA Vessey, JT Lockheart, MSK

Citation: Jv. St Peter et al., Factors associated with the risk of liver enzyme elevation in patients with type 2 diabetes treated with a thiazolidinedione, PHARMACOTHE, 21(2), 2001, pp. 183-188

Authors: Khan, MA St Peter, JV Breen, GA Hartley, GG Vessey, JT

Citation: Ma. Khan et al., Diabetes disease stage predicts weight loss outcomes with long-term appetite suppressants, OBES RES, 8(1), 2000, pp. 43-48

Authors: Mitchell, DY St Peter, JV Eusebio, RA Pallone, KA Kelly, SC Russell, DA Nesbitt, JD Thompson, GA Powell, JH

Citation: Dy. Mitchell et al., Effect of renal function on risedronate pharmacokinetics after a single oral dose, BR J CL PH, 49(3), 2000, pp. 215-222

Authors: Swan, SK St Peter, JV Lambrecht, LJ Hursting, MJ

Citation: Sk. Swan et al., Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects, PHARMACOTHE, 20(7), 2000, pp. 756-770

Authors: St Peter, JV Lambrecht, LJ Gunderson, BW Andersen, SA Gallagher, SC Swan, SK

Citation: Jv. St Peter et al., Pharmacokinetics of pilocarpine in subjects with varying degrees of renal function, J CLIN PHAR, 40(12), 2000, pp. 1470-1475

Authors: Khan, MA St Peter, JV Herzog, CA

Citation: Ma. Khan et al., Appetite-suppressant drugs and valvular heart disease - Reply, N ENG J MED, 340(6), 1999, pp. 478-479